Last reviewed · How we verify
Rockwell Medical Technologies, Inc. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| SFP | SFP | marketed | Intravenous iron replacement agent | Iron (Fe3+) for hemoglobin synthesis and erythropoiesis | Hematology / Nephrology | |
| Triferic AVNU | Triferic AVNU | marketed | Iron replacement agent | Iron (Fe3+) delivery system | Nephrology / Hematology |
Therapeutic area mix
- Hematology / Nephrology · 1
- Nephrology / Hematology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- American Regent, Inc. · 2 shared drug classes
- Ain Shams University · 1 shared drug class
- Albina Nowak, MD · 1 shared drug class
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 1 shared drug class
- Azad Pharma AG · 1 shared drug class
- CN NGANOU-GNINDJIO, MD, MSc · 1 shared drug class
- China-Japan Friendship Hospital · 1 shared drug class
- AMAG Pharmaceuticals, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Rockwell Medical Technologies, Inc.:
- Rockwell Medical Technologies, Inc. pipeline updates — RSS
- Rockwell Medical Technologies, Inc. pipeline updates — Atom
- Rockwell Medical Technologies, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Rockwell Medical Technologies, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rockwell-medical-technologies-inc. Accessed 2026-05-17.